Copper Cu 64 dotatate,a new diagnostic agent for somatostatin receptor-positive neuroendocrine tumors
10.13699/j.cnki.1001-6821.2024.12.028
- VernacularTitle:诊断生长抑素受体阳性神经内分泌肿瘤的新一代放射性试剂Copper Cu 64 dotatate
- Author:
Ming-Zhu XU
1
;
Chao-Yang CHEN
;
Ran WEI
;
Xuan-Ling ZHANG
;
Ying ZHOU
Author Information
1. 北京大学第一医院药剂科,北京 100034;中国药科大学基础医学与临床药学学院,江苏南京 210009
- Keywords:
Copper Cu 64 dotatate;
neuroendocrine tumors;
somatostatin receptor
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(12):1832-1834
- CountryChina
- Language:Chinese
-
Abstract:
On September 3,2020,the U.S.Food and Drug Administration(FDA)granted formal approval to Copper Cu 64 dotatate(commercially known as Detectnet),for its pivotal role in diagnosing somatostatin receptor(SSTR)positive neuroendocrine tumors(NETs)in adult patients.This innovative diagnostic agent,Copper Cu 64 dotatate,is a sophisticated radionuclide that selectively targets somatostatin receptors,facilitating the emission of positron(β+)radionuclides in a quantity conducive for high-resolution positron emission tomography(PET)imaging.This review delves into the intricate mechanisms of action,the dynamic pharmacokinetics,comprehensive clinical studies,and the safety profile of Copper Cu 64 dotatate,highlighting its significance in the realm of medical diagnostics.
